ArtVentive Medical has announced the first use of its Endoluminal Occlusion System (EOS) in the USA at The Johns Hopkins Hospital in Baltimore, where Kelvin Hong and Anobel Tamrazi performed a splenic artery occlusion using the device.
“The EOS device performed very well in a challenging clinical setting. We achieved immediate occlusion of the target vessel and concluded the case in rapid fashion,” stated Kelvin Hong, division chief of vascular and interventional radiology at Johns Hopkins Medical Institutions. “The unique ability to visualise the EOS device prior to deployment provides confidence in the placement of the device and enables precise delivery.”
Jim Graham, ArtVentive’s chief executive officer, commented, “Following our recent FDA clearance, this is an important milestone for our organisation and a statement to the tremendous efforts of our entire team over several years. We are excited to bring this proprietary technology to additional centres as we expand our commercialisation efforts in the USA, as well as in Europe.”
Leon Rudakov, president and chief technology officer, stated, “The EOS platform allows physicians to treat their patients effectively and efficiently. We believe the unique ability of the EOS device to provide a high level of visualisation and immediate occlusion enhances operator control and confidence during the procedure. These design characteristics allow physicians to provide a higher level of treatment and heightens the ability to efficiently address the clinical needs of their patients.”
